Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Yellow fever vaccine

Generic name
Yellow fever vaccine
Brand name
ATC Code
J07BL01

Pharmacokinetics in children

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Available formulations

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Dosages

Immunization against yellow fever
  • Subcutaneous
    • 6 months up to 9 months
      [1]
        • Children aged 6 to 9 months may only be vaccinated under special circumstances (e.g. during major outbreaks) and based on current official recommendations.
        • Children aged 6 months or more with HIV-positive mothers may be vaccinated if it has been shown that the child is not infected with HIV. Children who are infected with HIV may be vaccinated after consulting the HIV treating physicians and/or infectiologists.
    • ≥ 9 months
      [1]
      • 1.000 IU/dose, once only.
      • Administer at least 10 days before entering an endemically affected area:

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Renal impaiment in children > 3 months

No information available on dose adjustment in renal impairment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects in children

Very common (> 10%): irritability, loss of appetite, crying, drowsiness, pain at injection site, fever, vomiting

Common (1-10%): Erythema at site of injection and swelling at site of injection 

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications in children

Children younger than six months.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions in children

Children of ≥ 6 months with HIV-positive mothers may be vaccinated if it has been shown that they are not infected. If the child is HIV positive, consultation a paediatric team.

Live attenuated vaccines (e.g., yellow fever vaccine) should not be given to infants exposed to infliximab in utero until 12 months after birth. Administration of a live attenuated vaccine to a breastfed infant while the mother is receiving infliximab is not recommended unless serum levels of infliximab are undetectable in the infant. These infants may be at increased risk of infection, including severe disseminated infection that can become fatal. [DHPC]

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

References

  1. Sanofi Pasteur MSD, SmPC Stamaril (RVG17615) 04-12-2015, www.geneesmiddeleninformatiebank.nl
  2. Representatives of marketing authorisation holders of infliximab, DHPC Infliximab 07 maart 2022,, https://www.cbg-meb.nl/documenten/brieven/2022/03/08/dhpc-infliximab

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Changes

Changes